Formycon Wins Endorsement For Second EU Lucentis Rival
CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar
Executive Summary
Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.
You may also be interested in...
Stada And Xbrane Win EU Endorsement For Ranibizumab
Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.
What’s Next? Five Things To Look Out For In August
A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.
Polpharma Celebrates Being First With Natalizumab In Europe
Polpharma Biologics has claimed the first biosimilar natalizumab filing in Europe, after the European Medicines Agency accepted the firm’s marketing authorization application for review.